Fractyl Health (GUTS) Capital Expenditures (2023 - 2025)
Fractyl Health's (GUTS) quarterly Capital Expenditures came in at $3000.0 in Q4 2025, down 98.71% YoY from $233000.0 in Q4 2024, and down 62.5% on a QoQ basis from $8000.0 in Q3 2025.
Fractyl Health (GUTS) Capital Expenditures (2023 - 2025) Analysis & Trends
Fractyl Health (GUTS) has 3 years of Capital Expenditures data on file, last reported at $3000.0 in Q4 2025.
- Quarterly Capital Expenditures fell 98.71% year-over-year to $3000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $557000.0 (down 68.44% YoY) and the FY2025 annual result came in at $557000.0, down 68.44% from the prior year.
- Capital Expenditures eased to $3000.0 in Q4 2025, from $8000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $1.3 million in Q2 2024 to a low of -$54000.0 in Q3 2023.
- A 3-year average of $201083.3 and a median of $62500.0 in 2023 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2024 — Capital Expenditures jumped 2261.82% — and 2025, when it sank 98.71%.
- Tracing GUTS's Capital Expenditures over 3 years: stood at $70000.0 in 2023, then surged by 232.86% to $233000.0 in 2024, then slumped by 98.71% to $3000.0 in 2025.
- The last three Capital Expenditures figures came in at $3000.0 (Q4 2025), $8000.0 (Q3 2025), and $98000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.94 Bn | 132.09 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 86.59 Bn | 78.60 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 65.67 Bn | 60.49 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.81 Bn | 52.67 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 42.25 Bn | 37.15 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.76 Bn | 28.45 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.41 Bn | 10.02 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 251.02 Mn |
| 10 | Fractyl Health | 125.70 Mn | 125.70 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3,000.00 |
| Dec 31, 2025 | 3,000.00 |
| Sep 30, 2025 | 8,000.00 |
| Sep 30, 2025 | 8,000.00 |
| Jun 30, 2025 | 98,000.00 |
| Jun 30, 2025 | 98,000.00 |
| Mar 31, 2025 | 448,000.00 |
| Mar 31, 2025 | 448,000.00 |
| Dec 31, 2024 | 233,000.00 |
| Dec 31, 2024 | 233,000.00 |
| Sep 30, 2024 | 213,000.00 |
| Sep 30, 2024 | 213,000.00 |
| Jun 30, 2024 | 1.30 Mn |
| Jun 30, 2024 | 1.30 Mn |
| Mar 31, 2024 | 20,000.00 |
| Mar 31, 2024 | 20,000.00 |
| Dec 31, 2023 | 70,000.00 |
| Dec 31, 2023 | 70,000.00 |
| Sep 30, 2023 | -54,000.00 |
| Sep 30, 2023 | -54,000.00 |